Cardiac microvascular barrier function mediates the protection of tongxinluo against myocardial ischemia/reperfusion injury

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Qi, Kang ^a   Li, Lujin ^b   Li, Xiangdong ^a   Zhao, Jinglin ^a   Wang, Yang ^a   You, Shijie ^a   Hu, Fenghuan ^a   Zhang, Haitao ^a   Cheng, Yutong ^a   Kang, Sheng ^a   Cui, Hehe ^a   Duan, Lian ^a   Jin, Chen ^a   Zheng, Qingshan ^b   Yang, Yuejin ^a  

^a FUWAI HOSPITAL   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CARDIOVASCULAR AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MEMBRANE PROTEIN; PADGEM PROTEIN; PLAKOGLOBIN; SUR2 PROTEIN; TONGXINLUO; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; CARDIOTONIC AGENT; HERBACEOUS AGENT;

ARTICLE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HEART HEMODYNAMICS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HERBAL MEDICINE; HUMAN; MALE; NECROSIS SIZE; NO REFLOW SIZE; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; TREND STUDY; UPREGULATION; ANIMAL; CARDIAC MUSCLE; DRUG EFFECTS; HEART; HEMODYNAMICS; ISCHEMIC PRECONDITIONING; NO REFLOW PHENOMENON; PATHOLOGY; PIG; PRINCIPAL COMPONENT ANALYSIS; THEORETICAL MODEL;

SUIDAE;

ANIMALS; CARDIOTONIC AGENTS; DRUGS, CHINESE HERBAL; FEMALE; HEART; HEMODYNAMICS; ISCHEMIC PRECONDITIONING; MALE; MODELS, THEORETICAL; MYOCARDIUM; NO-REFLOW PHENOMENON; PRINCIPAL COMPONENT ANALYSIS; REPERFUSION INJURY; SWINE;

EID: 84924944004     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119846     Document Type: Article

References (62)

1. Karalliedde LD, Kappagoda CT. The challenge of traditional Chinese medicines for allopathic practitioners. Am J Physiol Heart Circ Physiol. 2009; 297: H1967-1969. doi: 10.1152/ajpheart.00944.2009 PMID: 19855052
2. Zhang L, Liu Y, Lu XT, Wu YL, Zhang C, Ji XP, et al. Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy. Am J Physiol Heart Circ Physiol. 2009; 297: H2004-2014. doi: 10.1152/ajpheart.00208.2009 PMID: 19801495
3. Zhang HT, Jia ZH, Zhang J, Ye ZK, Yang WX, Tian YQ, et al. No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: a randomized double-blind placebo-controlled multicenter clinical trial (ENLEAT Trial). Chin Med J (Engl). 2010; 123: 2858-2864. PMID: 21034597
4. Li XD, Yang YJ, Geng YJ, Jin C, Hu FH, Zhao JL, et al. Tongxinluo reduces myocardial no-reflow and ischemia-reperfusion injury by stimulating the phosphorylation of eNOS via the PKA pathway. Am J Physiol Heart Circ Physiol. 2010; 299: H1255-1261. doi: 10.1152/ajpheart.00459.2010 PMID: 20693395
5. Li XD, Yang YJ, Cheng YT, Dou KF, Tian Y, Meng XM. Protein kinase A-mediated cardioprotection of Tongxinluo relates to the inhibition of myocardial inflammation, apoptosis, and edema in reperfused swine hearts. Chin Med J (Engl). 2013; 126: 1469-1479. PMID: 23595379
6. Guo J, Gan XT, Haist JV, Rajapurohitam V, Zeidan A, Faruq NS, et al. Ginseng inhibits cardiomyocyte hypertrophy and heart failure via NHE-1 inhibition and attenuation of calcineurin activation. Circ Heart Fail. 2011; 4: 79-88. doi: 10.1161/CIRCHEARTFAILURE.110.957969 PMID: 20971938
7. Moey M, Gan XT, Huang CX, Rajapurohitam V, Martinez-Abundis E, Lui EM, et al. Ginseng reverses established cardiomyocyte hypertrophy and postmyocardial infarction-induced hypertrophy and heart failure. Circ Heart Fail. 2012; 5: 504-514. doi: 10.1161/CIRCHEARTFAILURE.112.967489 PMID: 22576957
8. Zhao JL YY, You SJ, Jing ZC, Wu YJ, et al. Beneficial effects of ischemic preconditioning on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. Acta Acad Med Sin. 2005; 27: 486-490.
9. Zhao JL, Yang YJ, Cui CJ, You SJ, Gao RL. Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel. Br J Pharmacol. 2006; 149: 243-249. PMID: 16921391
10. Yang YJ, Zhao JL, You SJ, Wu YJ, Jing ZC, Yang WX, et al. Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. Heart. 2006; 92: 1131-1137. PMID: 16387825
11. Zhao JL, Yang YJ, Chen JL, Kang LM, Wu Y, Gao RL. Nicorandil reduces myocardial no-reflow by protection of endothelial function via the activation of KATP channel. Clin Chim Acta. 2006; 374: 100-105. PMID: 16824503
12. Zhao JL, Yang YJ, You SJ, Jing ZC, Wu YJ, Cheng JL, et al. Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Coron Artery Dis. 2006; 17: 463-469. PMID: 16845255
13. Zhao JL, Yang YJ, Cui CJ, You SJ, Wu YJ, Gao RL. Different effects of adenosine and calcium channel blockade on myocardial no-reflow after acute myocardial infarction and reperfusion. Cardiovasc Drugs Ther. 2006; 20: 167-175. PMID: 16775665
14. Zhao JL, Yang YJ, You SJ, Cui CJ, Gao RL. Different effects of postconditioning on myocardial noreflow in the normal and hypercholesterolemic mini-swines. Microvasc Res. 2007; 73: 137-142. PMID: 17055004
15. Zhao J, Yang Y, you S, Cui C, Gao R. Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Int J Cardiol. 2007; 115: 334-341. PMID: 16824628
16. Yang YJ, Zhao JL, You SJ, Wu YJ, Jing ZC, Gao RL, et al. Post-infarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATP channel. Eur J Heart Fail. 2007; 9: 30-36. PMID: 16829188
17. Cheng YT, Yang YJ, Zhang HT, Qian HY, Zhao JL, Meng XM, et al. Pretreatment with Tongxinluo protects porcine myocardium from ischaemia/reperfusion injury through a nitric oxide related mechanism. Chin Med J (Engl). 2009; 122: 1529-1538. PMID: 19719943
18. Cheng YT, Luo FL, Zhang HT, Qian HY, Zhao JL, Yang YJ. Comparison of different administration protocol with rosuvastatin on no reflow and endothelial functional and structural integrity in a mini-swine model of acute infarction and reperfusion. Shandong Yi Yao. 2009; 49: 4-7.
19. Zhang HT YY, Wu YL, Cheng YT, Kang S, et al. Effectts of tongxinluo on mini-swine vascular endothelial integrity and myocardial no-reflow in early reperfusion of acute myocardial infarction. Natl Med J China. 2009; 89: 1421-1425.
20. Duan L, Yang YJ, Zhang HT, Cheng YT, Kang S, Gao R. Protective effect of Tongxinluo on mini-swine model of acute myocardial infarction and reperfusion damaged by oxidative stress. Chinese Journal of Pathophysiology. 2010; 26: 430-434.
21. Duan L, Yang YJ, Zhang HT, Zhao JL, Meng XM, Gao R. Protective effect of Tong-xin-luo on microvascular endothelium dysfunction in mini-swine model of acute myocardial infarction reperfusion. Shandong Yi Yao. 2010; 50: 3-6.
22. Li XD, Yang YJ, Zhao JL, Zhang HT, Cheng YT, Gao R. Ischemic preconditioning attenuates myocardial no-reflow and reperfusion injury after revascularization of acute myocardial infarction by reducing edema via the protein kinase A pathway. Chin J Cardiol. 2012; 40: 945-951.
23. Li XD, Cheng YT, Yang YJ, Meng XM, Zhao JL, Zhang HT, et al. PKA-mediated eNOS phosphorylation in the protection of ischemic preconditioning against no-reflow. Microvasc Res. 2012; 84: 44-54. doi: 10.1016/j.mvr.2012.04.002 PMID: 22542438
24. Li XD, Yang YJ, Geng YJ, Zhao JL, Zhang HT, Cheng YT, et al. Phosphorylation of endothelial NOS contributes to simvastatin protection against myocardial no-reflow and infarction in reperfused swine hearts: partially via the PKA signaling pathway. Acta Pharmacol Sin. 2012; 33: 879-887. doi: 10.1038/aps.2012.27 PMID: 22659627
25. Li XD, Yang YJ, Geng YJ, Cheng YT, Zhang HT, Zhao JL, et al. The cardioprotection of simvastatin in reperfused swine hearts relates to the inhibition of myocardial edema by modulating aquaporins via the PKA pathway. Int J Cardiol. 2013; 167: 2657-2666. doi: 10.1016/j.ijcard.2012.06.121 PMID: 22819122
26. Bekkers SC, Yazdani SK, Virmani R, Waltenberger J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol. 2010; 55: 1649-1660. doi: 10.1016/j.jacc.2009.12.037 PMID: 20394867
27. Wu ZQ, Li M, Chen J, Chi ZQ, Liu JG. Involvement of cAMP/cAMP-dependent protein kinase signaling pathway in regulation of Na+,K+-ATPase upon activation of opioid receptors by morphine. Mol Pharmacol. 2006; 69: 866-876. PMID: 16317112
28. Ikeno F, Inagaki K, Rezaee M, Mochly-Rosen D. Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage. Cardiovasc Res. 2007; 73: 699-709. PMID: 17234167
29. Gerczuk PZ, Kloner RA. An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol. 2012; 59: 969-978. doi: 10.1016/j.jacc.2011.07.054 PMID: 22402067
30. Milligan PA, Brown MJ, Marchant B, Martin SW, van der Graaf PH, Benson N, et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin Pharmacol Ther. 2013; 93: 502-514. doi: 10.1038/clpt.2013.54 PMID: 23588322
31. Kang S, Yang YJ, Wang QZ, Li Y, Tian Y, Cheng YT. Expressions of eNOS3 and Ve-cadherin in microvascular endothelium at 7-day of reperfused acute myocardial infarction. Cardiovasc Hematol Disord Drug Targets. 2009; 9: 107-117. PMID: 19519369
32. Bolli R, Becker L, Gross G, Mentzer R Jr., Balshaw D, Lathrop DA, et al. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res. 2004; 95: 125-134. PMID: 15271864
33. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013; 123: 92-100. doi: 10.1172/JCI62874 PMID: 23281415
34. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008; 72: 950-957. doi: 10.1002/ccd.21715 PMID: 19021281
35. Csonka C, Kupai K, Kocsis GF, Novak G, Fekete V, Bencsik P, et al. Measurement of myocardial infarct size in preclinical studies. J Pharmacol Toxicol Methods. 2010; 61: 163-170. doi: 10.1016/j.vascn.2010.02.014 PMID: 20188845
36. B OH, Bosch JA, Carroll D, Hemming K, Pilz S, Loerbroks A, et al. Evidence of a synergistic association between heart rate, inflammation, and cardiovascular mortality in patients undergoing coronary angiography. Eur Heart J. 2013; 34: 932-941. doi: 10.1093/eurheartj/ehs396 PMID: 23178644
37. Nicholson JK, Holmes E, Elliott P. The metabolome-wide association study: a new look at human disease risk factors. J Proteome Res. 2008; 7: 3637-3638. doi: 10.1021/pr8005099 PMID: 18707153
38. Li L, Huang X, Jia Z, Wu Y, Zheng Q. Evaluation of the impacts of homocysteine and hypoxia on vascular endothelial function based on the profiling of neuro-endocrine-immunity network in rats. Pharmacol Res. 2009; 60: 277-283. PMID: 19728401
39. Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol. 2004; 5: 261-270. PMID: 15071551
40. Ruder TD, Ebert LC, Khattab AA, Rieben R, Thali MJ, Kamat P. Edema is a sign of early acute myocardial infarction on post-mortem magnetic resonance imaging. Forensic Sci Med Pathol. 2013; 9: 501-505. doi: 10.1007/s12024-013-9459-x PMID: 23783421
41. Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med. 2010; 363: 689-691. doi: 10.1056/NEJMcibr1007320 PMID: 20818861
42. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci. 2008; 121: 2115-2122. doi: 10.1242/jcs.017897 PMID: 18565824
43. Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH, Yuan SY. Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev Mol Med. 2009; 11: e19. doi: 10.1017/S1462399409001112 PMID: 19563700
44. Galaup A, Gomez E, Souktani R, Durand M, Cazes A, Monnot C, et al. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation. 2012; 125: 140-149. doi: 10.1161/CIRCULATIONAHA.111.049072 PMID: 22086875
45. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013; 339: 161-166. doi: 10.1126/science.1230719 PMID: 23307733
46. Lee WW, Marinelli B, van der Laan AM, Sena BF, Gorbatov R, Leuschner F, et al. PET/MRI of inflammation in myocardial infarction. J Am Coll Cardiol. 2012; 59: 153-163. doi: 10.1016/j.jacc.2011.08.066 PMID: 22222080
47. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005; 437: 497-504. PMID: 16177780
48. Li Z, Jin ZQ. Ischemic preconditioning enhances integrity of coronary endothelial tight junctions. Biochem Biophys Res Commun. 2012; 425: 630-635. doi: 10.1016/j.bbrc.2012.07.130 PMID: 22846574
49. Maeng YS, Maharjan S, Kim JH, Park JH, Suk Yu Y, Kim YM, et al. Rk1, a ginsenoside, is a new blocker of vascular leakage acting through actin structure remodeling. PLoS One. 2013; 8: e68659. doi: 10.1371/journal.pone.0068659 PMID: 23894330
50. Giannotta M, Trani M, Dejana E. VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev Cell. 2013; 26: 441-454. doi: 10.1016/j.devcel.2013.08.020 PMID: 24044891
51. Clement LC, Mace C, Avila-Casado C, Joles JA, Kersten S, Chugh SS. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med. 2014; 20: 37-46. doi: 10.1038/nm.3396 PMID: 24317117
52. Bouleti C, Mathivet T, Coqueran B, Serfaty JM, Lesage M, Berland E, et al. Protective effects of angio-poietin- like 4 on cerebrovascular and functional damages in ischaemic stroke. Eur Heart J. 2013; 34: 3657-3668. doi: 10.1093/eurheartj/eht153 PMID: 23674618
53. Galaup A, Cazes A, Le Jan S, Philippe J, Connault E, Le Coz E, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci U S A. 2006; 103: 18721-18726. PMID: 17130448
54. Muscari C, Bonafe F, Gamberini C, Giordano E, Tantini B, Fattori M, et al. Early preconditioning prevents the loss of endothelial nitric oxide synthase and enhances its activity in the ischemic/reperfused rat heart. Life Sci. 2004; 74: 1127-1137. PMID: 14687653
55. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Bolli R. Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway. Circulation. 2007; 116: 535-544. PMID: 17606840
56. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res. 2006; 70: 240-253. PMID: 16545352
57. Yang C, Talukder MA, Varadharaj S, Velayutham M, Zweier JL. Early ischaemic preconditioning requires Akt- and PKA-mediated activation of eNOS via serine1176 phosphorylation. Cardiovasc Res. 2013; 97: 33-43. doi: 10.1093/cvr/cvs287 PMID: 22977010
58. O'Rourke B. Myocardial K(ATP) channels in preconditioning. Circ Res. 2000; 87: 845-855. PMID: 11073879
59. Bernardo NL D'Angelo M, Okubo S, Joy A, Kukreja RC. Am J Physiol. 1999; 276: H1323-1330. PMID: 10199858
60. Genda S, Miura T, Miki T, Ichikawa Y, Shimamoto K. K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol. 2002; 40: 1339-1346. PMID: 12383584
61. Facundo HT, de Paula JG, Kowaltowski AJ. Mitochondrial ATP-sensitive K+ channels prevent oxidative stress, permeability transition and cell death. J Bioenerg Biomembr. 2005; 37: 75-82. PMID: 15906152
62. Corada M. Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. Blood. 2001; 97: 1679-1684. PMID: 11238107